New drug combo aims to tackle Hard-to-Treat hodgkin lymphoma

NCT ID NCT03697408

Ongoing Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two drugs, itacitinib and everolimus, can help people with classical Hodgkin lymphoma that has returned or not responded to prior treatments. The trial is open to adults with measurable disease and aims to see how well the combination works in shrinking or eliminating tumors. Participants receive both drugs and are monitored for safety and response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: itacitinib and everolimus
What this could lead to: If successful, this drug combination could offer a new treatment option for people with Hodgkin lymphoma that has not responded to standard therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so the results may not apply to everyone. The combination may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLASSICAL HODGKIN LYMPHOMA

Contacts and locations

Locations

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.